Your browser doesn't support javascript.
loading
Response-adapted lenalidomide maintenance in newly diagnosed myeloma: results from the phase III GMMG-MM5 trial.
Goldschmidt, Hartmut; Mai, Elias K; Dürig, Jan; Scheid, Christof; Weisel, Katja C; Kunz, Christina; Bertsch, Uta; Hielscher, Thomas; Merz, Maximilian; Munder, Markus; Lindemann, Hans-Walter; Hügle-Dörr, Barbara; Tichy, Diana; Giesen, Nicola; Hose, Dirk; Seckinger, Anja; Huhn, Stefanie; Luntz, Steffen; Jauch, Anna; Elmaagacli, Ahmet; Rabold, Bernhard; Fuhrmann, Stephan; Brossart, Peter; Goerner, Martin; Bernhard, Helga; Hoffmann, Martin; Hillengass, Jens; Raab, Marc S; Blau, Igor W; Hänel, Mathias; Salwender, Hans J.
Afiliação
  • Goldschmidt H; Department of Internal Medicine V, University Hospital Heidelberg, Heidelberg, Germany. hartmut.goldschmidt@med.uni-heidelberg.de.
  • Mai EK; National Center for Tumor Diseases (NCT), Heidelberg, Germany. hartmut.goldschmidt@med.uni-heidelberg.de.
  • Dürig J; Department of Internal Medicine V, University Hospital Heidelberg, Heidelberg, Germany.
  • Scheid C; Department of Hematology, University Hospital Essen, Essen, Germany.
  • Weisel KC; Department of Internal Medicine I, University Hospital Cologne, Cologne, Germany.
  • Kunz C; Department of Hematology, Oncology and Immunology, University Hospital Tübingen, Tübingen, Germany.
  • Bertsch U; Department of Oncology, Hematology and Bone Marrow Transplantation with Section of Pneumology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
  • Hielscher T; Division of Biostatistics, German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Merz M; Department of Internal Medicine V, University Hospital Heidelberg, Heidelberg, Germany.
  • Munder M; National Center for Tumor Diseases (NCT), Heidelberg, Germany.
  • Lindemann HW; Division of Biostatistics, German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Hügle-Dörr B; Department of Internal Medicine V, University Hospital Heidelberg, Heidelberg, Germany.
  • Tichy D; Department of Internal Medicine III, University Medical Center Mainz, Mainz, Germany.
  • Giesen N; Department of Hematology and Oncology, Katholisches Krankenhaus Hagen, Hagen, Germany.
  • Hose D; Department of Internal Medicine V, University Hospital Heidelberg, Heidelberg, Germany.
  • Seckinger A; Division of Biostatistics, German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Huhn S; Department of Internal Medicine V, University Hospital Heidelberg, Heidelberg, Germany.
  • Luntz S; Department of Internal Medicine V, University Hospital Heidelberg, Heidelberg, Germany.
  • Jauch A; Department of Internal Medicine V, University Hospital Heidelberg, Heidelberg, Germany.
  • Elmaagacli A; Department of Internal Medicine V, University Hospital Heidelberg, Heidelberg, Germany.
  • Rabold B; Coordination Centre for Clinical Trials (KKS), Heidelberg, Germany.
  • Fuhrmann S; Institute of Human Genetics, University of Heidelberg, Heidelberg, Germany.
  • Brossart P; Department of Hematology and Oncology, Asklepios Hospital Hamburg St. Georg, Hamburg, Germany.
  • Goerner M; Coordination Centre for Clinical Trials (KKS), Heidelberg, Germany.
  • Bernhard H; Department of Hematology and Oncology, Helios Hospital Berlin Buch, Berlin, Germany.
  • Hoffmann M; University Hospital Bonn, Bonn, Germany.
  • Hillengass J; Department of Hematology, Oncology and Palliative Care, Klinikum Bielefeld, Bielefeld, Germany.
  • Raab MS; Internal Medicine V, Klinikum Darmstadt, Darmstadt, Germany.
  • Blau IW; Medical Clinic A, Klinikum Ludwigshafen, Ludwigshafen, Germany.
  • Hänel M; Department of Internal Medicine V, University Hospital Heidelberg, Heidelberg, Germany.
  • Salwender HJ; Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.
Leukemia ; 34(7): 1853-1865, 2020 07.
Article em En | MEDLINE | ID: mdl-32034285
Assuntos
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Transplante de Células-Tronco Hematopoéticas / Quimioterapia de Consolidação / Quimioterapia de Manutenção / Mieloma Múltiplo Tipo de estudo: Clinical_trials / Diagnostic_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Aged / Female / Humans / Male Idioma: En Revista: Leukemia Assunto da revista: HEMATOLOGIA / NEOPLASIAS Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Alemanha
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Transplante de Células-Tronco Hematopoéticas / Quimioterapia de Consolidação / Quimioterapia de Manutenção / Mieloma Múltiplo Tipo de estudo: Clinical_trials / Diagnostic_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Aged / Female / Humans / Male Idioma: En Revista: Leukemia Assunto da revista: HEMATOLOGIA / NEOPLASIAS Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Alemanha